Bavarian Nordic maintains phase III plans despite vaccine worries
Follow-up data from phase II trials of the vaccine maker’s candidate against Covid-19 concerns CEO Paul Chaplin, but it will have ”absolutely no” consequences for the company’s phase III trial.
by ulrich quistgaard, translated by christian radich hoffman
Even though Bavarian Nordic’s management finds it worrying that the company’s vaccine candidate against Covid-19 is most effective against the early variants of the virus, the company’s current phase III trial will continue regardless, Bavarian’s VP of investor relations and communications, Rolf Sass Sørensen, maintains in a mail to MedWatch.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
